Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1Neoplasm Metastasis 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × tasquinimod × Clear all
NCT02057666 2021-04-23

TasQ003

Ipsen

Phase 3 Terminated
146 enrolled 13 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT01234311 2015-10-21

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Active Biotech AB

Phase 3 Completed
1,245 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡